NCT06075940View on ClinicalTrials.gov

Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions
Critical Limb-Threatening IschemiaCritical Limb IschemiaCritical Lower Limb Ischemia
Interventions
DEVICE

MAGNITUDE BRS

Treatment with the MAGNITUDE Scaffold

Trial Locations (1)

2031

RECRUITING

Prince of Wales Hopsital, Randwick

All Listed Sponsors
lead

R3 Vascular Inc.

INDUSTRY